Paper Details

  1. Home
  2. Paper Details

Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia.

Author: CayssialsEmilie, EtienneGabriel, HuguetFrançoise, NicoliniFranck-Emmanuel, RéaDelphine

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Ponatinib is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia. Its dosage should be tailored to the patient's risk profile, including prior response to treatment and mutational status.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: Ponatinib exhibits a high inhibition potency on wild-type and most mutated forms of the AREAS COVERED: Based on pharmacological findings and international guidelines on chronic myeloid leukemia and cardiovascular risk management, as well as on the most recent data collected in real-l...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/17474086.2023.2234084

データ提供：米国国立医学図書館（NLM）

Optimizing Ponatinib Dosing: Tailoring Treatment for Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a type of cancer that affects the blood and bone marrow. This article provides a comprehensive overview of ponatinib, a tyrosine kinase inhibitor used to treat CML, focusing on dose optimization and the management of cardiovascular risk. The authors propose a decision-tree approach for selecting the appropriate ponatinib dose based on factors such as patient response to previous treatments, mutational status, and cardiovascular risk profile.

Personalized Therapy for CML: Finding the Right Dose

The authors emphasize the importance of individualizing ponatinib treatment by carefully selecting the appropriate dose for each patient. This personalized approach can help optimize therapeutic efficacy while minimizing potential side effects. The decision-tree approach provides a structured framework for making informed decisions about ponatinib dosing, considering various factors relevant to the individual patient.

Navigating CML Treatment: Managing Cardiovascular Risk

The study highlights the importance of managing cardiovascular risk in CML patients receiving ponatinib. This medication can potentially increase the risk of cardiovascular events, so careful monitoring and proactive management of cardiovascular risk factors, such as hypertension and dyslipidemia, are crucial for ensuring patient safety and improving overall health outcomes. Close collaboration between the patient and their healthcare team is essential for achieving optimal management of CML and associated cardiovascular risks.

Dr.Camel's Conclusion

This article provides valuable insights into the management of chronic myeloid leukemia with ponatinib. The authors emphasize the importance of individualized treatment strategies, including dose optimization and careful monitoring of cardiovascular risk. By understanding these key considerations, healthcare professionals can provide more personalized and effective care for patients with CML, ultimately improving their chances of long-term survival and a better quality of life.
Date :
  1. Date Completed 2023-11-02
  2. Date Revised 2023-11-14
Further Info :

Pubmed ID

37427999

DOI: Digital Object Identifier

10.1080/17474086.2023.2234084

Related Literature

Article Analysis
・Effects of ponatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.